
Global Semi-Solid Dosage Form Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Semi-Solid Dosage Form market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Semi-Solid Dosage Form is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Semi-Solid Dosage Form is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Semi-Solid Dosage Form market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Semi-Solid Dosage Form is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Semi-Solid Dosage Form market include Aclaris Therapeutics, Inc., Akorn Inc. (US), Allergan plc, Almirall, S.A, Bausch Health Companies, Biofrontera, Inc., Cipla Ltd, Crescita Therapeutics Inc. and Crown Laboratories Inc., etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Semi-Solid Dosage Form, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Semi-Solid Dosage Form, also provides the sales of main regions and countries. Of the upcoming market potential for Semi-Solid Dosage Form, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Semi-Solid Dosage Form sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Semi-Solid Dosage Form market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Semi-Solid Dosage Form sales, projected growth trends, production technology, application and end-user industry.
Semi-Solid Dosage Form Segment by Company
Aclaris Therapeutics, Inc.
Akorn Inc. (US)
Allergan plc
Almirall, S.A
Bausch Health Companies
Biofrontera, Inc.
Cipla Ltd
Crescita Therapeutics Inc.
Crown Laboratories Inc.
Encore Dermatology, Inc.
Glenmark Pharmaceuticals
Hisamitsu Pharmaceutical
Ingenus Pharmaceuticals
LEO Pharma
Mylan N.V.
Novartis AG
Perrigo Pharma
Taro Pharmaceutical Industries Ltd.
Teligent Pharma
Bayer AG
GlaxoSmithKline plc
Merck & Co
Johnson & Johnson
Nestlé SA
Sun Pharmaceuticals
Semi-Solid Dosage Form Segment by Type
Ointments
Gels
Others
Semi-Solid Dosage Form Segment by Application
Nasal Cavity
Skin
Vaginal Cavity
Rectal Cavity
Others
Semi-Solid Dosage Form Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Semi-Solid Dosage Form status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Semi-Solid Dosage Form market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Semi-Solid Dosage Form significant trends, drivers, influence factors in global and regions.
6. To analyze Semi-Solid Dosage Form competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Semi-Solid Dosage Form market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Semi-Solid Dosage Form and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Semi-Solid Dosage Form.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Semi-Solid Dosage Form market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Semi-Solid Dosage Form industry.
Chapter 3: Detailed analysis of Semi-Solid Dosage Form manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Semi-Solid Dosage Form in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Semi-Solid Dosage Form in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
According to APO Research, the global Semi-Solid Dosage Form market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Semi-Solid Dosage Form is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Semi-Solid Dosage Form is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Semi-Solid Dosage Form market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Semi-Solid Dosage Form is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Semi-Solid Dosage Form market include Aclaris Therapeutics, Inc., Akorn Inc. (US), Allergan plc, Almirall, S.A, Bausch Health Companies, Biofrontera, Inc., Cipla Ltd, Crescita Therapeutics Inc. and Crown Laboratories Inc., etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Semi-Solid Dosage Form, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Semi-Solid Dosage Form, also provides the sales of main regions and countries. Of the upcoming market potential for Semi-Solid Dosage Form, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Semi-Solid Dosage Form sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Semi-Solid Dosage Form market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Semi-Solid Dosage Form sales, projected growth trends, production technology, application and end-user industry.
Semi-Solid Dosage Form Segment by Company
Aclaris Therapeutics, Inc.
Akorn Inc. (US)
Allergan plc
Almirall, S.A
Bausch Health Companies
Biofrontera, Inc.
Cipla Ltd
Crescita Therapeutics Inc.
Crown Laboratories Inc.
Encore Dermatology, Inc.
Glenmark Pharmaceuticals
Hisamitsu Pharmaceutical
Ingenus Pharmaceuticals
LEO Pharma
Mylan N.V.
Novartis AG
Perrigo Pharma
Taro Pharmaceutical Industries Ltd.
Teligent Pharma
Bayer AG
GlaxoSmithKline plc
Merck & Co
Johnson & Johnson
Nestlé SA
Sun Pharmaceuticals
Semi-Solid Dosage Form Segment by Type
Ointments
Gels
Others
Semi-Solid Dosage Form Segment by Application
Nasal Cavity
Skin
Vaginal Cavity
Rectal Cavity
Others
Semi-Solid Dosage Form Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Semi-Solid Dosage Form status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Semi-Solid Dosage Form market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Semi-Solid Dosage Form significant trends, drivers, influence factors in global and regions.
6. To analyze Semi-Solid Dosage Form competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Semi-Solid Dosage Form market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Semi-Solid Dosage Form and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Semi-Solid Dosage Form.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Semi-Solid Dosage Form market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Semi-Solid Dosage Form industry.
Chapter 3: Detailed analysis of Semi-Solid Dosage Form manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Semi-Solid Dosage Form in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Semi-Solid Dosage Form in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Table of Contents
210 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Semi-Solid Dosage Form Sales Value (2020-2031)
- 1.2.2 Global Semi-Solid Dosage Form Sales Volume (2020-2031)
- 1.2.3 Global Semi-Solid Dosage Form Sales Average Price (2020-2031)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
- 2 Semi-Solid Dosage Form Market Dynamics
- 2.1 Semi-Solid Dosage Form Industry Trends
- 2.2 Semi-Solid Dosage Form Industry Drivers
- 2.3 Semi-Solid Dosage Form Industry Opportunities and Challenges
- 2.4 Semi-Solid Dosage Form Industry Restraints
- 3 Semi-Solid Dosage Form Market by Company
- 3.1 Global Semi-Solid Dosage Form Company Revenue Ranking in 2024
- 3.2 Global Semi-Solid Dosage Form Revenue by Company (2020-2025)
- 3.3 Global Semi-Solid Dosage Form Sales Volume by Company (2020-2025)
- 3.4 Global Semi-Solid Dosage Form Average Price by Company (2020-2025)
- 3.5 Global Semi-Solid Dosage Form Company Ranking (2023-2025)
- 3.6 Global Semi-Solid Dosage Form Company Manufacturing Base and Headquarters
- 3.7 Global Semi-Solid Dosage Form Company Product Type and Application
- 3.8 Global Semi-Solid Dosage Form Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Semi-Solid Dosage Form Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.9.3 2024 Semi-Solid Dosage Form Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
- 4 Semi-Solid Dosage Form Market by Type
- 4.1 Semi-Solid Dosage Form Type Introduction
- 4.1.1 Ointments
- 4.1.2 Gels
- 4.1.3 Others
- 4.2 Global Semi-Solid Dosage Form Sales Volume by Type
- 4.2.1 Global Semi-Solid Dosage Form Sales Volume by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Semi-Solid Dosage Form Sales Volume by Type (2020-2031)
- 4.2.3 Global Semi-Solid Dosage Form Sales Volume Share by Type (2020-2031)
- 4.3 Global Semi-Solid Dosage Form Sales Value by Type
- 4.3.1 Global Semi-Solid Dosage Form Sales Value by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Semi-Solid Dosage Form Sales Value by Type (2020-2031)
- 4.3.3 Global Semi-Solid Dosage Form Sales Value Share by Type (2020-2031)
- 5 Semi-Solid Dosage Form Market by Application
- 5.1 Semi-Solid Dosage Form Application Introduction
- 5.1.1 Nasal Cavity
- 5.1.2 Skin
- 5.1.3 Vaginal Cavity
- 5.1.4 Rectal Cavity
- 5.1.5 Others
- 5.2 Global Semi-Solid Dosage Form Sales Volume by Application
- 5.2.1 Global Semi-Solid Dosage Form Sales Volume by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Semi-Solid Dosage Form Sales Volume by Application (2020-2031)
- 5.2.3 Global Semi-Solid Dosage Form Sales Volume Share by Application (2020-2031)
- 5.3 Global Semi-Solid Dosage Form Sales Value by Application
- 5.3.1 Global Semi-Solid Dosage Form Sales Value by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Semi-Solid Dosage Form Sales Value by Application (2020-2031)
- 5.3.3 Global Semi-Solid Dosage Form Sales Value Share by Application (2020-2031)
- 6 Semi-Solid Dosage Form Regional Sales and Value Analysis
- 6.1 Global Semi-Solid Dosage Form Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Semi-Solid Dosage Form Sales by Region (2020-2031)
- 6.2.1 Global Semi-Solid Dosage Form Sales by Region: 2020-2025
- 6.2.2 Global Semi-Solid Dosage Form Sales by Region (2026-2031)
- 6.3 Global Semi-Solid Dosage Form Sales Value by Region: 2020 VS 2024 VS 2031
- 6.4 Global Semi-Solid Dosage Form Sales Value by Region (2020-2031)
- 6.4.1 Global Semi-Solid Dosage Form Sales Value by Region: 2020-2025
- 6.4.2 Global Semi-Solid Dosage Form Sales Value by Region (2026-2031)
- 6.5 Global Semi-Solid Dosage Form Market Price Analysis by Region (2020-2025)
- 6.6 North America
- 6.6.1 North America Semi-Solid Dosage Form Sales Value (2020-2031)
- 6.6.2 North America Semi-Solid Dosage Form Sales Value Share by Country, 2024 VS 2031
- 6.7 Europe
- 6.7.1 Europe Semi-Solid Dosage Form Sales Value (2020-2031)
- 6.7.2 Europe Semi-Solid Dosage Form Sales Value Share by Country, 2024 VS 2031
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Semi-Solid Dosage Form Sales Value (2020-2031)
- 6.8.2 Asia-Pacific Semi-Solid Dosage Form Sales Value Share by Country, 2024 VS 2031
- 6.9 South America
- 6.9.1 South America Semi-Solid Dosage Form Sales Value (2020-2031)
- 6.9.2 South America Semi-Solid Dosage Form Sales Value Share by Country, 2024 VS 2031
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Semi-Solid Dosage Form Sales Value (2020-2031)
- 6.10.2 Middle East & Africa Semi-Solid Dosage Form Sales Value Share by Country, 2024 VS 2031
- 7 Semi-Solid Dosage Form Country-level Sales and Value Analysis
- 7.1 Global Semi-Solid Dosage Form Sales by Country: 2020 VS 2024 VS 2031
- 7.2 Global Semi-Solid Dosage Form Sales Value by Country: 2020 VS 2024 VS 2031
- 7.3 Global Semi-Solid Dosage Form Sales by Country (2020-2031)
- 7.3.1 Global Semi-Solid Dosage Form Sales by Country (2020-2025)
- 7.3.2 Global Semi-Solid Dosage Form Sales by Country (2026-2031)
- 7.4 Global Semi-Solid Dosage Form Sales Value by Country (2020-2031)
- 7.4.1 Global Semi-Solid Dosage Form Sales Value by Country (2020-2025)
- 7.4.2 Global Semi-Solid Dosage Form Sales Value by Country (2026-2031)
- 7.5 USA
- 7.5.1 USA Semi-Solid Dosage Form Sales Value Growth Rate (2020-2031)
- 7.5.2 USA Semi-Solid Dosage Form Sales Value Share by Type, 2024 VS 2031
- 7.5.3 USA Semi-Solid Dosage Form Sales Value Share by Application, 2024 VS 2031
- 7.6 Canada
- 7.6.1 Canada Semi-Solid Dosage Form Sales Value Growth Rate (2020-2031)
- 7.6.2 Canada Semi-Solid Dosage Form Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Canada Semi-Solid Dosage Form Sales Value Share by Application, 2024 VS 2031
- 7.7 Mexico
- 7.6.1 Mexico Semi-Solid Dosage Form Sales Value Growth Rate (2020-2031)
- 7.6.2 Mexico Semi-Solid Dosage Form Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Mexico Semi-Solid Dosage Form Sales Value Share by Application, 2024 VS 2031
- 7.8 Germany
- 7.8.1 Germany Semi-Solid Dosage Form Sales Value Growth Rate (2020-2031)
- 7.8.2 Germany Semi-Solid Dosage Form Sales Value Share by Type, 2024 VS 2031
- 7.8.3 Germany Semi-Solid Dosage Form Sales Value Share by Application, 2024 VS 2031
- 7.9 France
- 7.9.1 France Semi-Solid Dosage Form Sales Value Growth Rate (2020-2031)
- 7.9.2 France Semi-Solid Dosage Form Sales Value Share by Type, 2024 VS 2031
- 7.9.3 France Semi-Solid Dosage Form Sales Value Share by Application, 2024 VS 2031
- 7.10 U.K.
- 7.10.1 U.K. Semi-Solid Dosage Form Sales Value Growth Rate (2020-2031)
- 7.10.2 U.K. Semi-Solid Dosage Form Sales Value Share by Type, 2024 VS 2031
- 7.10.3 U.K. Semi-Solid Dosage Form Sales Value Share by Application, 2024 VS 2031
- 7.11 Italy
- 7.11.1 Italy Semi-Solid Dosage Form Sales Value Growth Rate (2020-2031)
- 7.11.2 Italy Semi-Solid Dosage Form Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Italy Semi-Solid Dosage Form Sales Value Share by Application, 2024 VS 2031
- 7.12 Spain
- 7.12.1 Spain Semi-Solid Dosage Form Sales Value Growth Rate (2020-2031)
- 7.12.2 Spain Semi-Solid Dosage Form Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Spain Semi-Solid Dosage Form Sales Value Share by Application, 2024 VS 2031
- 7.13 Russia
- 7.13.1 Russia Semi-Solid Dosage Form Sales Value Growth Rate (2020-2031)
- 7.13.2 Russia Semi-Solid Dosage Form Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Russia Semi-Solid Dosage Form Sales Value Share by Application, 2024 VS 2031
- 7.14 Netherlands
- 7.14.1 Netherlands Semi-Solid Dosage Form Sales Value Growth Rate (2020-2031)
- 7.14.2 Netherlands Semi-Solid Dosage Form Sales Value Share by Type, 2024 VS 2031
- 7.14.3 Netherlands Semi-Solid Dosage Form Sales Value Share by Application, 2024 VS 2031
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Semi-Solid Dosage Form Sales Value Growth Rate (2020-2031)
- 7.15.2 Nordic Countries Semi-Solid Dosage Form Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Nordic Countries Semi-Solid Dosage Form Sales Value Share by Application, 2024 VS 2031
- 7.16 China
- 7.16.1 China Semi-Solid Dosage Form Sales Value Growth Rate (2020-2031)
- 7.16.2 China Semi-Solid Dosage Form Sales Value Share by Type, 2024 VS 2031
- 7.16.3 China Semi-Solid Dosage Form Sales Value Share by Application, 2024 VS 2031
- 7.17 Japan
- 7.17.1 Japan Semi-Solid Dosage Form Sales Value Growth Rate (2020-2031)
- 7.17.2 Japan Semi-Solid Dosage Form Sales Value Share by Type, 2024 VS 2031
- 7.17.3 Japan Semi-Solid Dosage Form Sales Value Share by Application, 2024 VS 2031
- 7.18 South Korea
- 7.18.1 South Korea Semi-Solid Dosage Form Sales Value Growth Rate (2020-2031)
- 7.18.2 South Korea Semi-Solid Dosage Form Sales Value Share by Type, 2024 VS 2031
- 7.18.3 South Korea Semi-Solid Dosage Form Sales Value Share by Application, 2024 VS 2031
- 7.19 India
- 7.19.1 India Semi-Solid Dosage Form Sales Value Growth Rate (2020-2031)
- 7.19.2 India Semi-Solid Dosage Form Sales Value Share by Type, 2024 VS 2031
- 7.19.3 India Semi-Solid Dosage Form Sales Value Share by Application, 2024 VS 2031
- 7.20 Australia
- 7.20.1 Australia Semi-Solid Dosage Form Sales Value Growth Rate (2020-2031)
- 7.20.2 Australia Semi-Solid Dosage Form Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Australia Semi-Solid Dosage Form Sales Value Share by Application, 2024 VS 2031
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Semi-Solid Dosage Form Sales Value Growth Rate (2020-2031)
- 7.21.2 Southeast Asia Semi-Solid Dosage Form Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Southeast Asia Semi-Solid Dosage Form Sales Value Share by Application, 2024 VS 2031
- 7.22 Brazil
- 7.22.1 Brazil Semi-Solid Dosage Form Sales Value Growth Rate (2020-2031)
- 7.22.2 Brazil Semi-Solid Dosage Form Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Brazil Semi-Solid Dosage Form Sales Value Share by Application, 2024 VS 2031
- 7.23 Argentina
- 7.23.1 Argentina Semi-Solid Dosage Form Sales Value Growth Rate (2020-2031)
- 7.23.2 Argentina Semi-Solid Dosage Form Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Argentina Semi-Solid Dosage Form Sales Value Share by Application, 2024 VS 2031
- 7.24 Chile
- 7.24.1 Chile Semi-Solid Dosage Form Sales Value Growth Rate (2020-2031)
- 7.24.2 Chile Semi-Solid Dosage Form Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Chile Semi-Solid Dosage Form Sales Value Share by Application, 2024 VS 2031
- 7.25 Colombia
- 7.25.1 Colombia Semi-Solid Dosage Form Sales Value Growth Rate (2020-2031)
- 7.25.2 Colombia Semi-Solid Dosage Form Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Colombia Semi-Solid Dosage Form Sales Value Share by Application, 2024 VS 2031
- 7.26 Peru
- 7.26.1 Peru Semi-Solid Dosage Form Sales Value Growth Rate (2020-2031)
- 7.26.2 Peru Semi-Solid Dosage Form Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Peru Semi-Solid Dosage Form Sales Value Share by Application, 2024 VS 2031
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Semi-Solid Dosage Form Sales Value Growth Rate (2020-2031)
- 7.27.2 Saudi Arabia Semi-Solid Dosage Form Sales Value Share by Type, 2024 VS 2031
- 7.27.3 Saudi Arabia Semi-Solid Dosage Form Sales Value Share by Application, 2024 VS 2031
- 7.28 Israel
- 7.28.1 Israel Semi-Solid Dosage Form Sales Value Growth Rate (2020-2031)
- 7.28.2 Israel Semi-Solid Dosage Form Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Israel Semi-Solid Dosage Form Sales Value Share by Application, 2024 VS 2031
- 7.29 UAE
- 7.29.1 UAE Semi-Solid Dosage Form Sales Value Growth Rate (2020-2031)
- 7.29.2 UAE Semi-Solid Dosage Form Sales Value Share by Type, 2024 VS 2031
- 7.29.3 UAE Semi-Solid Dosage Form Sales Value Share by Application, 2024 VS 2031
- 7.30 Turkey
- 7.30.1 Turkey Semi-Solid Dosage Form Sales Value Growth Rate (2020-2031)
- 7.30.2 Turkey Semi-Solid Dosage Form Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Turkey Semi-Solid Dosage Form Sales Value Share by Application, 2024 VS 2031
- 7.31 Iran
- 7.31.1 Iran Semi-Solid Dosage Form Sales Value Growth Rate (2020-2031)
- 7.31.2 Iran Semi-Solid Dosage Form Sales Value Share by Type, 2024 VS 2031
- 7.31.3 Iran Semi-Solid Dosage Form Sales Value Share by Application, 2024 VS 2031
- 7.32 Egypt
- 7.32.1 Egypt Semi-Solid Dosage Form Sales Value Growth Rate (2020-2031)
- 7.32.2 Egypt Semi-Solid Dosage Form Sales Value Share by Type, 2024 VS 2031
- 7.32.3 Egypt Semi-Solid Dosage Form Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 Aclaris Therapeutics, Inc.
- 8.1.1 Aclaris Therapeutics, Inc. Comapny Information
- 8.1.2 Aclaris Therapeutics, Inc. Business Overview
- 8.1.3 Aclaris Therapeutics, Inc. Semi-Solid Dosage Form Sales, Value and Gross Margin (2020-2025)
- 8.1.4 Aclaris Therapeutics, Inc. Semi-Solid Dosage Form Product Portfolio
- 8.1.5 Aclaris Therapeutics, Inc. Recent Developments
- 8.2 Akorn Inc. (US)
- 8.2.1 Akorn Inc. (US) Comapny Information
- 8.2.2 Akorn Inc. (US) Business Overview
- 8.2.3 Akorn Inc. (US) Semi-Solid Dosage Form Sales, Value and Gross Margin (2020-2025)
- 8.2.4 Akorn Inc. (US) Semi-Solid Dosage Form Product Portfolio
- 8.2.5 Akorn Inc. (US) Recent Developments
- 8.3 Allergan plc
- 8.3.1 Allergan plc Comapny Information
- 8.3.2 Allergan plc Business Overview
- 8.3.3 Allergan plc Semi-Solid Dosage Form Sales, Value and Gross Margin (2020-2025)
- 8.3.4 Allergan plc Semi-Solid Dosage Form Product Portfolio
- 8.3.5 Allergan plc Recent Developments
- 8.4 Almirall, S.A
- 8.4.1 Almirall, S.A Comapny Information
- 8.4.2 Almirall, S.A Business Overview
- 8.4.3 Almirall, S.A Semi-Solid Dosage Form Sales, Value and Gross Margin (2020-2025)
- 8.4.4 Almirall, S.A Semi-Solid Dosage Form Product Portfolio
- 8.4.5 Almirall, S.A Recent Developments
- 8.5 Bausch Health Companies
- 8.5.1 Bausch Health Companies Comapny Information
- 8.5.2 Bausch Health Companies Business Overview
- 8.5.3 Bausch Health Companies Semi-Solid Dosage Form Sales, Value and Gross Margin (2020-2025)
- 8.5.4 Bausch Health Companies Semi-Solid Dosage Form Product Portfolio
- 8.5.5 Bausch Health Companies Recent Developments
- 8.6 Biofrontera, Inc.
- 8.6.1 Biofrontera, Inc. Comapny Information
- 8.6.2 Biofrontera, Inc. Business Overview
- 8.6.3 Biofrontera, Inc. Semi-Solid Dosage Form Sales, Value and Gross Margin (2020-2025)
- 8.6.4 Biofrontera, Inc. Semi-Solid Dosage Form Product Portfolio
- 8.6.5 Biofrontera, Inc. Recent Developments
- 8.7 Cipla Ltd
- 8.7.1 Cipla Ltd Comapny Information
- 8.7.2 Cipla Ltd Business Overview
- 8.7.3 Cipla Ltd Semi-Solid Dosage Form Sales, Value and Gross Margin (2020-2025)
- 8.7.4 Cipla Ltd Semi-Solid Dosage Form Product Portfolio
- 8.7.5 Cipla Ltd Recent Developments
- 8.8 Crescita Therapeutics Inc.
- 8.8.1 Crescita Therapeutics Inc. Comapny Information
- 8.8.2 Crescita Therapeutics Inc. Business Overview
- 8.8.3 Crescita Therapeutics Inc. Semi-Solid Dosage Form Sales, Value and Gross Margin (2020-2025)
- 8.8.4 Crescita Therapeutics Inc. Semi-Solid Dosage Form Product Portfolio
- 8.8.5 Crescita Therapeutics Inc. Recent Developments
- 8.9 Crown Laboratories Inc.
- 8.9.1 Crown Laboratories Inc. Comapny Information
- 8.9.2 Crown Laboratories Inc. Business Overview
- 8.9.3 Crown Laboratories Inc. Semi-Solid Dosage Form Sales, Value and Gross Margin (2020-2025)
- 8.9.4 Crown Laboratories Inc. Semi-Solid Dosage Form Product Portfolio
- 8.9.5 Crown Laboratories Inc. Recent Developments
- 8.10 Encore Dermatology, Inc.
- 8.10.1 Encore Dermatology, Inc. Comapny Information
- 8.10.2 Encore Dermatology, Inc. Business Overview
- 8.10.3 Encore Dermatology, Inc. Semi-Solid Dosage Form Sales, Value and Gross Margin (2020-2025)
- 8.10.4 Encore Dermatology, Inc. Semi-Solid Dosage Form Product Portfolio
- 8.10.5 Encore Dermatology, Inc. Recent Developments
- 8.11 Glenmark Pharmaceuticals
- 8.11.1 Glenmark Pharmaceuticals Comapny Information
- 8.11.2 Glenmark Pharmaceuticals Business Overview
- 8.11.3 Glenmark Pharmaceuticals Semi-Solid Dosage Form Sales, Value and Gross Margin (2020-2025)
- 8.11.4 Glenmark Pharmaceuticals Semi-Solid Dosage Form Product Portfolio
- 8.11.5 Glenmark Pharmaceuticals Recent Developments
- 8.12 Hisamitsu Pharmaceutical
- 8.12.1 Hisamitsu Pharmaceutical Comapny Information
- 8.12.2 Hisamitsu Pharmaceutical Business Overview
- 8.12.3 Hisamitsu Pharmaceutical Semi-Solid Dosage Form Sales, Value and Gross Margin (2020-2025)
- 8.12.4 Hisamitsu Pharmaceutical Semi-Solid Dosage Form Product Portfolio
- 8.12.5 Hisamitsu Pharmaceutical Recent Developments
- 8.13 Ingenus Pharmaceuticals
- 8.13.1 Ingenus Pharmaceuticals Comapny Information
- 8.13.2 Ingenus Pharmaceuticals Business Overview
- 8.13.3 Ingenus Pharmaceuticals Semi-Solid Dosage Form Sales, Value and Gross Margin (2020-2025)
- 8.13.4 Ingenus Pharmaceuticals Semi-Solid Dosage Form Product Portfolio
- 8.13.5 Ingenus Pharmaceuticals Recent Developments
- 8.14 LEO Pharma
- 8.14.1 LEO Pharma Comapny Information
- 8.14.2 LEO Pharma Business Overview
- 8.14.3 LEO Pharma Semi-Solid Dosage Form Sales, Value and Gross Margin (2020-2025)
- 8.14.4 LEO Pharma Semi-Solid Dosage Form Product Portfolio
- 8.14.5 LEO Pharma Recent Developments
- 8.15 Mylan N.V.
- 8.15.1 Mylan N.V. Comapny Information
- 8.15.2 Mylan N.V. Business Overview
- 8.15.3 Mylan N.V. Semi-Solid Dosage Form Sales, Value and Gross Margin (2020-2025)
- 8.15.4 Mylan N.V. Semi-Solid Dosage Form Product Portfolio
- 8.15.5 Mylan N.V. Recent Developments
- 8.16 Novartis AG
- 8.16.1 Novartis AG Comapny Information
- 8.16.2 Novartis AG Business Overview
- 8.16.3 Novartis AG Semi-Solid Dosage Form Sales, Value and Gross Margin (2020-2025)
- 8.16.4 Novartis AG Semi-Solid Dosage Form Product Portfolio
- 8.16.5 Novartis AG Recent Developments
- 8.17 Perrigo Pharma
- 8.17.1 Perrigo Pharma Comapny Information
- 8.17.2 Perrigo Pharma Business Overview
- 8.17.3 Perrigo Pharma Semi-Solid Dosage Form Sales, Value and Gross Margin (2020-2025)
- 8.17.4 Perrigo Pharma Semi-Solid Dosage Form Product Portfolio
- 8.17.5 Perrigo Pharma Recent Developments
- 8.18 Taro Pharmaceutical Industries Ltd.
- 8.18.1 Taro Pharmaceutical Industries Ltd. Comapny Information
- 8.18.2 Taro Pharmaceutical Industries Ltd. Business Overview
- 8.18.3 Taro Pharmaceutical Industries Ltd. Semi-Solid Dosage Form Sales, Value and Gross Margin (2020-2025)
- 8.18.4 Taro Pharmaceutical Industries Ltd. Semi-Solid Dosage Form Product Portfolio
- 8.18.5 Taro Pharmaceutical Industries Ltd. Recent Developments
- 8.19 Teligent Pharma
- 8.19.1 Teligent Pharma Comapny Information
- 8.19.2 Teligent Pharma Business Overview
- 8.19.3 Teligent Pharma Semi-Solid Dosage Form Sales, Value and Gross Margin (2020-2025)
- 8.19.4 Teligent Pharma Semi-Solid Dosage Form Product Portfolio
- 8.19.5 Teligent Pharma Recent Developments
- 8.20 Bayer AG
- 8.20.1 Bayer AG Comapny Information
- 8.20.2 Bayer AG Business Overview
- 8.20.3 Bayer AG Semi-Solid Dosage Form Sales, Value and Gross Margin (2020-2025)
- 8.20.4 Bayer AG Semi-Solid Dosage Form Product Portfolio
- 8.20.5 Bayer AG Recent Developments
- 8.21 GlaxoSmithKline plc
- 8.21.1 GlaxoSmithKline plc Comapny Information
- 8.21.2 GlaxoSmithKline plc Business Overview
- 8.21.3 GlaxoSmithKline plc Semi-Solid Dosage Form Sales, Value and Gross Margin (2020-2025)
- 8.21.4 GlaxoSmithKline plc Semi-Solid Dosage Form Product Portfolio
- 8.21.5 GlaxoSmithKline plc Recent Developments
- 8.22 Merck & Co
- 8.22.1 Merck & Co Comapny Information
- 8.22.2 Merck & Co Business Overview
- 8.22.3 Merck & Co Semi-Solid Dosage Form Sales, Value and Gross Margin (2020-2025)
- 8.22.4 Merck & Co Semi-Solid Dosage Form Product Portfolio
- 8.22.5 Merck & Co Recent Developments
- 8.23 Johnson & Johnson
- 8.23.1 Johnson & Johnson Comapny Information
- 8.23.2 Johnson & Johnson Business Overview
- 8.23.3 Johnson & Johnson Semi-Solid Dosage Form Sales, Value and Gross Margin (2020-2025)
- 8.23.4 Johnson & Johnson Semi-Solid Dosage Form Product Portfolio
- 8.23.5 Johnson & Johnson Recent Developments
- 8.24 Nestlé SA
- 8.24.1 Nestlé SA Comapny Information
- 8.24.2 Nestlé SA Business Overview
- 8.24.3 Nestlé SA Semi-Solid Dosage Form Sales, Value and Gross Margin (2020-2025)
- 8.24.4 Nestlé SA Semi-Solid Dosage Form Product Portfolio
- 8.24.5 Nestlé SA Recent Developments
- 8.25 Sun Pharmaceuticals
- 8.25.1 Sun Pharmaceuticals Comapny Information
- 8.25.2 Sun Pharmaceuticals Business Overview
- 8.25.3 Sun Pharmaceuticals Semi-Solid Dosage Form Sales, Value and Gross Margin (2020-2025)
- 8.25.4 Sun Pharmaceuticals Semi-Solid Dosage Form Product Portfolio
- 8.25.5 Sun Pharmaceuticals Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Semi-Solid Dosage Form Value Chain Analysis
- 9.1.1 Semi-Solid Dosage Form Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Semi-Solid Dosage Form Sales Mode & Process
- 9.2 Semi-Solid Dosage Form Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Semi-Solid Dosage Form Distributors
- 9.2.3 Semi-Solid Dosage Form Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.